Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers

EMBO Molecular Medicine

  ^{1    2    2    3    4    5    5    5    5    5    6    7} 

[1] Department of Child Neurology, Children′s Hospital, University of Helsinki, Helsinki, Finland;Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;Minerva Foundation Institute for Medical Research, Helsinki, Finland;Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland;Research Programs Unit, Diabetes and Obesity, Obesity Research Unit, University of Helsinki, Helsinki, Finland;Abdominal Centre, Endocrinology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland;Research Programs Unit, Molecular Neurology, Biomedicum‐Helsinki, University of Helsinki, Helsinki, Finland;Research Programs Unit, Molecular Neurology, Biomedicum‐Helsinki, University of Helsinki, Helsinki, Finland;Department of Neurosciences, Helsinki University Hospital, Helsinki, Finland;Neuroscience Centre, Helsinki Institute Life Science, University of Helsinki, Helsinki, Finland;Research Programs Unit, Molecular Neurology, Biomedicum‐Helsinki, University of Helsinki, Helsinki, Finland;Genetics Research Centre, Molecular and Clinical Sciences Institute, St. George's University of London, London, UK;

关键词: biomarker;    inclusion body myositis;    metabolomics;    mitochondrial diseases;   

DOI  :  10.15252/emmm.201809091

来源: publisher

【 授权许可】

Unknown